ロード中...
Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation
• Metastatic CSMD3 mutated HGSOC showed objective and sustained response to pembrolizumab. • The tumor was massively infiltrated by CD8(+) T cells while PD-L1 TPS was at 10%. • CSMD3 mutated HGSOC showed up-regulation of CCL5 and CXCL9.
保存先:
| 出版年: | Gynecol Oncol Rep |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7322246/ https://ncbi.nlm.nih.gov/pubmed/32613071 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2020.100600 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|